Drug recall · July 30, 2014
Orphenadrine Citrate Extended Release Tablets recall
Why: Failed Dissolution Specifications: Product found to be out of specification (OOS) during stability testing.
Class III: unlikely to cause harm, but breaks the rules (for example a labeling error).
The recall
- Product
Orphenadrine Citrate Extended Release Tablets, 100 mg a)100-count bottle, (NDC 0185-0022-01) b) 1000-count bottle, (NDC 0185-0022-10), Rx only, Manufactured by Sandoz Inc., Princeton, NJ 08540.
- Lots / codes
Lot # DM1316; Exp. 05/16 Lot # DM1318; Exp. 05/16
- Quantity
- 781,000 extended release tablets
- Company
- Sandoz Inc, Princeton, NJ
- Distribution
- Nationwide
- Initiated
- July 11, 2014 · Voluntary: Firm initiated
- Classified
- July 23, 2014
- Reported
- July 30, 2014
- Ended
- July 10, 2017
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Orphenadrine
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.